Our ActiveTargeting™ assays allow real-time monitoring of tumor events based in non-invasive blood draws. Certain markers, such as ALK, can be readily detected in the blood in levels that correlate with tumor expression using our core platform. Expressed mutations, including those that influence drug resistance, can also be readily detected. Using these technologies, oncologists can monitor tumor status non-invasively and in real-time so treatment can be altered as soon as resistance develops. These tests are also helpful for pharmaceutical companies looking for potential indicators of drug response or resistance and may be a surrogate of efficacy. We have also validated and filed patents on accurately quantifying circulating ALK and related RNA and are working with a number of pharmaceutical companies to inexpensively and rapidly offer the ALK Active Targeting RNA screen for patients at multiple time points in clinical trials, optimized in our CLIA laboratory with next day reporting.